Document:

Amendment to Supply and Distribution Rights Agreement

 EXHIBIT 10.1 
 Confidential Treatment requested. 
 Confidential portions of this 
 document have been redacted 
 and have been
separately filed 
 with the Commission 
 AMENDMENT TO SUPPLY AND DISTRIBUTION RIGHTS AGREEMENT 
 This AMENDMENT TO SUPPLY AND DISTRIBUTION RIGHTS AGREEMENT
(“Amendment”) is made as of 12th July, 2006 by and between AngioDynamics, Inc., a corporation
incorporated under the laws of Delaware, with its principal place of business located at Queensbury, New York, USA (“AngioDynamics”) and Bioniche Pharma Group Limited, a corporation incorporated under the laws of Ireland, with a principal
place of business located at Inverin, County Galway, Ireland (“Bioniche”). 
 RECITALS 
 WHEREAS, AngioDynamics and Bioniche are Parties to a Supply and Distribution Rights Agreement dated as of October 17, 2005
(“Agreement”); and 
 WHEREAS, AngioDynamics and Bioniche desire to amend the Agreement but only to the extent set forth in
this Amendment. 
 THEREFORE, in consideration of the foregoing premises and the mutual promises contained in this Amendment and other
valuable consideration, the receipt of which is acknowledged, the Parties agree as follows: 
 1. DEFINITIONS. 
 1.1 Unless otherwise defined in this Amendment, all capitalized terms shall have the same meanings as set forth in the Agreement. 
 1.2 FIELD. Section 1.1 m) of the Agreement is deleted and replaced with the following: 
 m) “Field” shall mean the distribution and sale of the Product to any and all Persons, for use in the treatment of varicose veins or other vascular
indications. 
 1.3 A new Section 1.1 gg) of the Agreement is added, as follows: 
 gg) “Actual Selling Price” shall mean AngioDynamics’ actual revenues from the sale of each concentration of Product in any particular Calendar
Quarter exclusive of trade discounts (in the nature of discounts for prompt payment). 

 2. SUBCONTRACTING. Section 2.6 is deleted and replaced with the following: 
 2.6 Subcontracting. 
 a) AngioDynamics shall
not subcontract to, or otherwise make any provision or arrangement with any Person (excluding any Affiliate; provided that AngioDynamics shall warranty and remain responsible for the performance by its Affiliate of its obligations hereunder) for the
distribution and sale of Product, without the prior written consent of Bioniche, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, the parties agree that this Section 2.6 a) shall not
impede the right of AngioDynamics to freely sell Product to Group Purchasing Organizations and wholesalers. 
 b) Bioniche shall not
subcontract to, or otherwise make any provision or arrangement with any person (excluding an Affiliate; provided that Bioniche shall warranty and remain responsible for the performance by its Affiliate of its obligations hereunder) for the
manufacture of Product, without the prior written consent of AngioDynamics, which consent shall not be unreasonably withheld, conditioned, or delayed. 
 3. MINIMUM PURCHASE REQUIREMENTS; RUN RATES. 
 3.1 Section 6.2 of the Agreement is renamed
“Minimums - General” and the text thereof is deleted in its entirety and replaced with the following: 
 6.2 Minimums –
General. 
 a) In partial consideration for the exclusive rights in the Territory in the Field being granted it under this Agreement, AngioDynamics
shall use reasonable efforts to purchase the minimum purchase requirements set forth in Schedule “D” hereto for the Product for each Contract Year other than the second Contract Year; failing which, the provisions of the following
paragraph of this Section 6.2 shall apply. 
 Any Contract Year, other than the second Contract Year, in which AngioDynamics does not achieve the
minimum purchase requirements for that Contract Year shall be hereinafter referred to as a “Deficient Contract Year.” Bioniche’s sole remedy for AngioDynamics’ failure to meet the minimum purchase requirements set forth in
Schedule “D” in any Deficient Contract Year shall be to convert the exclusive license and distributor status of AngioDynamics in the Field into a non-exclusive relationship following ninety (90) days written notice to AngioDynamics.
Notwithstanding the foregoing, AngioDynamics shall be able to cure any noticed failure to meet the minimum purchase requirements by doing the following within the ninety (90) day notice period: (i) purchasing an amount of Product equal to
the difference between the amount of Product actually purchased by AngioDynamics in the Deficient Contract Year and AngioDynamics’ minimum purchase requirements for the Deficient Contract Year; and (ii) purchasing an amount of Product
equal to fifteen percent (15%) of its annual minimum purchase requirements for the then-current Contract Year. If AngioDynamics fully complies with (i) and (ii) above, Bioniche shall have no right to convert the exclusive license and
distributor status of AngioDynamics into a non-exclusive relationship. Any amount of Product purchased pursuant to (i) above shall not apply to the minimum purchase requirements for the then-current Contract Year, but the amount of Product
purchased pursuant to (ii) above shall apply to the minimum purchase requirements of the then-current Contract Year. 
 b) Notwithstanding the
foregoing, in any Deficient Contract Year, if AngioDynamics has failed to meet the minimum purchase requirements set forth in Schedule “D” and has not cured such failure pursuant to Section 6.2 a), but has purchased sufficient amounts
of Product to meet the minimum purchase requirements set forth in the original Agreement between AngioDynamics and Bioniche dated October 17, 2005, or has used the method to cure its failure to meet its minimum purchase requirements as set
forth in Section 6.2 a) and has thereby purchased sufficient Product to meet the minimum purchase requirements as set forth in the original Agreement between AngioDynamics and Bioniche dated October 17, 2005, Bioniche’s sole remedy
shall be to convert the exclusive license and distributor status of AngioDynamics in the Field into a non-exclusive relationship following the ninety (90) day notice period set forth in Section 6.2 a) except that AngioDynamics shall
continue to be the exclusive seller and distributor of Product in the Territory in relation to the following Persons whose professional practice involves the treatment of vascular disorders or conditions: (i) General Surgeons;
(ii) Vascular Surgeons; (iii) General/Vascular Surgeons; (iv) Interventional Radiologists; (v) Cardiovascular Surgeons; (vi) Cardiothoracic Surgeons; and (vii) Cardiologists. 
  

 2 

 For greater clarity, the minimum purchase requirements set forth in the original Agreement between AngioDynamics and
Bioniche dated October 17, 2005 are as follows: 
  

					
	•	  	Third year:	  	*** units/*** Product boxes
			
	•	  	Fourth year:	  	*** units/*** Product boxes
			
	•	  	Fifth year:	  	*** units/*** Product boxes

 c) The parties shall negotiate in good faith to establish the minimum purchase requirements for Contract Years six
and thereafter pursuant to the provisions of Schedule “D.” During such negotiations, the parties shall set out two (2) tiers of minimum purchase requirements for AngioDynamics. Failure to meet the first, lower tier of minimum purchase
requirements and failure to cure pursuant to Section 6.2 a) shall allow Bioniche, as its sole remedy for such failure, to convert the exclusive license and distributor status of AngioDynamics in the Field into a non-exclusive relationship
following the ninety (90) day notice period set forth in Section 6.2 a). If AngioDynamics fails to meet the second, higher tier of minimum purchase requirements, but meets the first, lower tier of minimum purchase requirements or has used
the method to cure its failure to meet the first, lower tier of minimum purchase requirements, Bioniche’s sole remedy shall be to convert the exclusive license and distributor status of AngioDynamics in the Field into a non-exclusive
relationship following the ninety (90) day notice period set forth in Section 6.2 a) except that AngioDynamics shall continue to be the exclusive seller and distributor of Product in the Territory in relation to the following Persons whose
professional practice involves the treatment of vascular disorders or conditions: (i) General Surgeons; (ii) Vascular Surgeons; (iii) General/Vascular Surgeons; (iv) Interventional Radiologists; (v) Cardiovascular Surgeons;
(vi) Cardiothoracic Surgeons; and (vii) Cardiologists. 
 3.2 New Sections 6.3, 6.4, 6.5, 6.6 and 6.7 of the Agreement are added,
as follows (and existing Section 6.3 shall now be designated as Section 6.8 and existing Section 6.4 shall now be designated as Section 6.9): 
 6.3 Minimums-Second Contract Year. During the second Contract Year (i.e. the period beginning July 1, 2006 and ending June 30, 2007), AngioDynamics shall purchase at least an amount of Product which will result in a
minimum total payment of $3,600,000.00 from AngioDynamics to Bioniche for Product based upon the Purchase Price for Product as set forth in Schedule “E” hereto. In addition, during the second Contract Year, AngioDynamics will place at
least one purchase order for Product in each of the following periods: June 1, 2006 to September 30, 2006; October 1, 2006 to December 31, 2006; January 1, 2007 to March 31, 2007; and April 1, 2007 to
May 31, 2007. 
 If AngioDynamics fails to purchase at least $3,600,000.00 worth of Product (based upon the Purchase Price as set forth in Schedule
“E” hereto) in the second Contract Year, such Product to be ordered by April 30, 2007, Bioniche’s sole remedy shall be the receipt of a payment from AngioDynamics to Bioniche in an amount equal to the difference between
$3,600,000.00 and the amount paid or to be paid by AngioDynamics to Bioniche for Product ordered by April 30, 2007 within the second Contract Year, which amount shall be paid by AngioDynamics to Bioniche on or before June 30, 2007. For
greater certainty, except as otherwise specifically provided for in Section 6.6, AngioDynamics shall be required to purchase the minimum units of Product for the second Contract Year on a “take or pay” basis; it being understood that
any failure on the part of AngioDynamics to order such minimum units of Product for the second Contract Year shall not relieve AngioDynamics of its obligation to pay Bioniche for such Product hereunder and that Bioniche shall not be obligated to
deliver any Product in exchange for the price paid for such unordered Product. 
  

	***	Confidential material redacted and filed separately with the Commission. 

  

 3 

 6.4 Run Rates. Without limiting its obligations under Section 6.2, during the third, fourth and fifth
Contract Years, respectively, AngioDynamics shall be required to achieve commercial sales in the Territory resulting in a “run rate” of at least ***, *** and *** total boxes of Product per month (respectively). For the purposes hereof,
“run rate” shall mean AngioDynamics’ monthly sales of Product to third Person customers, less any returns received in that month. Should AngioDynamics fail to fulfill its run rate obligations under this Section 6.4 for three
(3) consecutive months, without prejudice to its rights under Section 6.2, Bioniche’s sole remedy shall be to convert the exclusive license and distributor status of AngioDynamics in the Field into a non-exclusive relationship, upon
sixty (60) days written notice given by Bioniche to such effect, except that AngioDynamics shall continue to be the exclusive seller and distributor of Product in the Territory in relation to the following Persons whose professional practice
involves the treatment of vascular disorders or conditions: (i) General Surgeons; (ii) Vascular Surgeons; (iii) General/Vascular Surgeons; (iv) Interventional Radiologists; (v) Cardiovascular Surgeons;
(vi) Cardiothoracic Surgeons; and (vii) Cardiologists. 
 6.5 Outstanding Obligations of Bioniche. The Parties agree that, within
twenty one (21) days after the date of execution of this Amendment, Bioniche and its Affiliates shall have taken all reasonable commercial efforts to terminate any existing relationships or outstanding commitments with third Persons relating to
the sale and/or distribution of Product in the Territory. If, at any time after the date which is twenty one (21) days after the date of execution of this Amendment, Bioniche or its Affiliates are required pursuant to the terms of an agreement
existing prior to the date of execution of this Amendment to deliver Product to third Persons for sale and/or use in the Territory: (i) all units of such Product shall be credited towards AngioDynamics’ minimum purchase quantities set out
in Section 6.2 or 6.3, as the case may be; and (ii) all units of such Product shall be credited towards AngioDynamics’ “run rates” set out in Section 6.4; and (iii) an amount calculated on the basis of the number
of such units of Product sold by Bioniche or its Affiliates and AngioDynamics’ Actual Selling Price shall be credited against the $3,600,000.00 “take or pay” obligation under Section 6.3. 
 6.6 Exceptions. Notwithstanding anything to the contrary herein contained, AngioDynamics shall not be responsible for failing to achieve the minimum
purchase or run rate requirements established for it hereunder if such failure is directly attributable to: (i) the failure by Bioniche to deliver a sufficient quantity of the Product which satisfies the Specifications in response to purchase
orders placed in accordance with Section 7.7 hereof; and/or (ii) an Event of Force Majeure, as defined in Section 7.10 hereof. 
 6.7
Second Entry Product. In the event that a Second Entry Product enters the market in the Territory at any time during the Term, any annual minimum purchase requirements and any run rates agreed to hereunder, in each case, for periods after
the end of the second Contract Year shall be automatically reduced by fifty (50%) percent. Such decrease shall be on a going forward basis only, with a pro rata effect being calculated for any partial Contract Year after the second Contract
Year. 
 4. PAYMENTS; ETC. 
 4.1 A new Section 7.1 a) of the Agreement is added, as follows (and the existing Sections 7.1 a) and b) are re-lettered accordingly): 
 a) pay Bioniche non-refundable milestone fees of: 
 (i) Five Hundred Thousand Dollars
($500,000), payable within thirty (30) days after the date on which AngioDynamics’ cumulative sales of Products in the Territory exceed Ten Million Dollars ($10,000,000); 
 (ii) One Million Dollars ($1,000,000), payable within thirty (30) days after the date on which AngioDynamics’ cumulative sales
of Products in the Territory exceed Twenty Five Million Dollars ($25,000,000); and 
  

 4 

 (iii) One Million Dollars ($1,000,000), payable within thirty (30) days after the
date on which AngioDynamics’ cumulative sales of Products in the Territory exceed Fifty Million Dollars ($50,000,000). 
 For greater certainty,
cumulative sales shall be the running total of all sales of Products throughout the Term, calculated on the basis of AngioDynamics’ Actual Selling Price (as defined in 1.3 of this Amendment) at the time such sale was made. 
 Notwithstanding the foregoing, if at the time any of the milestone fees in (i), (ii) or (iii) above becomes payable, Bioniche has converted the entire or any
portion of the exclusive license and distributor status of AngioDynamics under this Agreement into a non-exclusive relationship pursuant to Section 6.2 or 6.4, AngioDynamics shall not have to pay to Bioniche such milestone fee or any subsequent
milestone fees. For one non-limiting example, if AngioDynamics’ exclusive license and distributor status in the Field has been converted to a non-exclusive relationship except that AngioDynamics continues to be the exclusive seller and
distributor of Product in relation to the following Persons whose professional practice involves the treatment of vascular disorders or conditions: (i) General Surgeons; (ii) Vascular Surgeons; (iii) General/Vascular Surgeons;
(iv) Interventional Radiologists; (v) Cardiovascular Surgeons; (vi) Cardiothoracic Surgeons; and (vii) Cardiologists, AngioDynamics shall not have to pay any subsequent milestone fees. 
 If AngioDynamics’ entire exclusive license and distributor status in the Field has been converted to a non-exclusive relationship pursuant to Section 6.2 or
6.4 herein, or if AngioDynamics’ exclusive license and distributor status in the Field has been converted to a non-exclusive relationship except that AngioDynamics continues to be the exclusive seller and distributor of Product in relation to
the following Persons whose professional practice involves the treatment of vascular disorders or conditions: (i) General Surgeons; (ii) Vascular Surgeons; (iii) General/Vascular Surgeons; (iv) Interventional Radiologists;
(v) Cardiovascular Surgeons; (vi) Cardiothoracic Surgeons; and (vii) Cardiologists, pursuant to Section 6.2 or 6.4 herein, and Bioniche has appointed another Person, other than AngioDynamics, as an exclusive distributor of
Product in any remaining portion of the Field, then AngioDynamics shall be entitled to receive from Bioniche an immediate return of any and all milestone fees previously paid to Bioniche pursuant to (i), (ii) and/or (iii) above.

 4.2 Existing Section 7.1 b) (re-lettered 7.1 c)) is deleted and replaced with the following: 
 c) make the minimum annual purchases of and achieve the “run-rates” for Product as provided in Sections 6.2 to 6.4, inclusive, hereof; which purchases, subject
to Section 7.4 hereof, will be supplied by Bioniche at a Purchase Price calculated in accordance with Schedule “E” hereto. 
 4.3 Existing Section 7.2 a) is amended by changing the reference to “under Subsection 7.1(a)” in the first sentence thereof to read “under Subsections 7.1a) and b)”. 
 4.4 The second paragraph of Section 7.4, beginning “Bioniche agrees and promises”, is deleted in its entirety. If AngioDynamics’
exclusive license and distributor status in the Field has been converted to a non-exclusive relationship except that AngioDynamics continues to be the exclusive seller and distributor of Product in relation to the following Persons whose
professional practice involves the treatment of vascular disorders or conditions: (i) General Surgeons; (ii) Vascular Surgeons; (iii) General/Vascular Surgeons; (iv) Interventional Radiologists; (v) Cardiovascular Surgeons;

  

 5 

 (vi) Cardiothoracic Surgeons; and (vii) Cardiologists, pursuant to Section 6.2 or 6.4 herein, then such
second paragraph shall be reinserted into the Agreement. For greater clarity, the second paragraph of Section 7.4 reads as follows: 
 Bioniche agrees
and promises that Bioniche’s price for Product sold to AngioDynamics hereunder as an exclusive distributor shall always be the lowest price which Bioniche or its Affiliates offers, charges, or accepts in full payment for the Product from
Bioniche’s or its Affiliates’ most favored customer in the Territory including, without limitation, another distributor, unless otherwise prohibited by applicable Laws. 
 5. INDEMNIFICATION 
 5.1 Existing
Section 8.4 a) is amended by deleting item (i) therein and replacing it with the following: 
 (i) any breach by Bioniche or its Affiliates of any
representations or warranties or obligations to AngioDynamics hereunder (including, without limitation, any third party claim relating to Bioniche’s or its Affiliates’ termination of any existing obligations in accordance with
Section 6.5 and/or Bioniche’s or its Affiliates’ failure to comply with any such existing obligations); 
 6. TERM;
TERMINATION 
 6.1 Existing Section 9.1 of the Agreement is deleted in its entirety and replaced with the following: 
 9.1 Term. This Agreement shall come into effect as of the Effective Date and shall continue in force until the end of the seventh (7th) Contract Year;
unless sooner terminated by either Party in accordance with Section 9.2 or extended in accordance with Section 9.7, below (the initial term, together with any extension or renewal term hereunder, referred to herein as the
“Term”). Thereafter, this Agreement will automatically renew for additional consecutive three (3) year periods, unless expressly terminated by either Party on written notice to the other Party at least one hundred and twenty
(120) calendar days prior to the end of the then current Term or otherwise terminated under Section 9.2 or 9.3. 
 6.2 Existing
Section 9.2 of the Agreement shall be deleted in its entirety and replaced with the following: 
 9.2 Termination by Either Party. Either
Party may terminate this Agreement by giving notice to the other Party: 
  

	 	a)	if the other Party becomes bankrupt, is placed into the hands of a trustee, receiver, or manager on behalf of creditors as to the whole or a substantial part of its business, makes
an assignment for the benefit of creditors, or ceases to carry on business; or 

  

	 	b)	if the other Party commits any material breach hereof and remains in breach thirty (30) days after written notice thereof; except for breaches by AngioDynamics in respect of
non-payment of any monies owing hereunder, which shall be governed by Section 9.3. AngioDynamics’ failure to meet the minimum purchase requirements set forth in Section 6.2, Section 6.3 or Schedule “D” shall not
constitute a material breach and remedies for such failure will be governed by Section 6.2 or Section 6.3, as applicable. AngioDynamics’ failure to meet the run rates set forth in Section 6.4 shall not constitute a material
breach and remedies for such failure will be governed by Section 6.4. 

  

 6 

 6.3 A new Section 9.7 of the Agreement is added, as follows: 
 9.7 Extension of Term. Subject always to Sections 9.2 and 9.3 hereof, in the event AngioDynamics has made any one or more milestone payments under
Section 7.1 a) hereof, AngioDynamics shall have the right to extend the Term, as follows: 
  

	 	(i)	following payment of the milestone payment under Section 7.1a)(i), AngioDynamics shall be entitled to extend the then current Term by one (1) Contract Year;

  

	 	(ii)	following payment of the milestone payment under Section 7.1a)(ii), AngioDynamics shall be entitled to extend the then current Term by two (2) additional Contract Years;
and 

  

	 	(iii)	following payment of the milestone payment under Section 7.1a)(iii), AngioDynamics shall be entitled to extend the then current Term by two (2) additional Contract Years.

 For greater certainty, any period of extension pursuant to (i), (ii) or (iii) above shall be considered an extension of the then
current Term. Thus, Bioniche shall have no right to send notice of non-renewal pursuant to Section 9.1 until one hundred twenty (120) days before the then current Term (including any periods of extension pursuant to this Section 9.7)
expires. 
 7. SCHEDULE D. Schedule D shall be deleted in its entirety and replaced with the following: 
 SCHEDULE “D” 
 to the

 Supply and Distribution Rights Agreement 
 dated October 17, 2005 
 by and between 
 AngioDynamics, Inc. (“AngioDynamics”) and Bioniche Pharma Group Limited (“Bioniche”) 
 MINIMUM PURCHASE REQUIREMENTS 
 AngioDynamics shall
achieve the following minimum purchase requirement of total vials/units in the second Contract Year of the Term of the Agreement: 
  

					
	•	 	Second Contract Year:	  	$3,600,000.00 worth of Product as per Section 6.3 of the Agreement

 AngioDynamics will use reasonable efforts to achieve the following minimum purchase requirements of total
vials/units in the third, fourth and fifth Contract Years of the Term of the Agreement: 
  

					
	•	 	Third Contract Year:	  	*** units/*** Product boxes
			
	•	 	Fourth Contract Year:	  	*** units/*** Product boxes
			
	•	 	Fifth Contract Year:	  	*** units/*** Product boxes

 At least twelve (12) months prior to the end of the fifth Contract Year, the Parties shall enter discussions
in good faith with respect to establishing minimum purchase requirements for the sixth and seventh Contract Years of the Term. In the unlikely event that the Parties are unable to agree on minimum purchase requirements for the sixth and seventh
Contract Years of the Term on or before the end of the first Calendar Quarter in the fifth Contract Year, the minimum purchase requirements for the sixth and seventh Contract Years shall be equal to the minimum purchase requirements for the fifth
Contract Year. The Parties shall 
  

	***	Confidential material redacted and filed separately with the Commission. 

  

 7 

 negotiate in good faith with respect to establishing minimum purchase requirements for the Contract Years extending
beyond the seventh Contract Year. If the Parties are unable to agree upon the minimum purchase requirements for any Contract Year beyond the seventh Contract Year within the first Calendar Quarter of the preceding Contract Year, the minimum purchase
requirements for the succeeding Contract Year shall be equal to the minimum purchase requirements for the preceding Contract Year. 
 Note: Total units are irrespective of concentration. (1 vial = 1 unit) (1 box = 5 units) 
  

 8 

 8. SCHEDULE E. Schedule E shall be deleted in its entirety and replaced with the following:

 SCHEDULE “E” 
 to the 
 Supply and Distribution Rights Agreement 
 dated October 17, 2005 
 by and between 
 AngioDynamics, Inc. (“AngioDynamics”) and Bioniche Pharma Group Limited (“Bioniche”) 
 PURCHASE PRICE 
 All pricing for 1% and 3% vials shall
be per box of Product. Each box of Product shall contain five (5) vials, each vial containing two (2) milliliters of Sotradecol. One unit shall equal one vial of Product. 
 The Purchase Price for the 1% solution of Product shall be $*** per box ($*** per unit). 
 The Purchase Price for the
3 % solution of Product shall be $*** per box ($*** per unit). 
 For greater certainty, it is understood and agreed between the Parties that Bioniche
shall have no control over (and shall not be responsible for setting) the AngioDynamics Actual Selling Price. 
 9. REFERENCES TO TRANSFER
PRICE. All references to “Transfer Price” within the Agreement shall be deleted and replaced with the phrase “Purchase Price”. 
 10. OTHER TERMS AND CONDITIONS UNCHANGED. AngioDynamics and Bioniche agree that all other terms and conditions of the Agreement shall remain unchanged and in full force and effect and all such other terms and
conditions are hereby ratified and confirmed. 
 11. COUNTERPARTS. This Amendment may be executed in counterparts with the same force
and effect as if each of the signatories had executed the same instrument. Delivery of an executed signature page to this Amendment by facsimile transmission shall be as effective as delivery of a manually signed counterpart. 
  

	***	Confidential material redacted and filed separately with the Commission. 

  

 9 

 IN WITNESS WHEREOF, the Parties have each caused the Amendment to be signed and delivered by their
duly authorized representative as of the date first written above. 
  

			
	BIONICHE PHARMA GROUP LIMITED
		
	By:	 	 /s/ John Kavanagh

	Name:	 	John Kavanagh
	Title:	 	Managing Director
	
	Date:30 June 2006
	
	ANGIODYNAMICS, INC.
		
	By:	 	 /s/ Robert M. Rossell

	Name:	 	Robert M. Rossell
	Title:	 	Vice President, Marketing
	
	Date:12 July 2006

  

 10Asset Purchase Agreement

 EXHIBIT 10.2 
 Confidential Treatment requested. 
 Confidential portions of this 
 document have been redacted 
 and have been
separately filed 
 with the Commission. 
 ASSET PURCHASE AGREEMENT 
 This ASSET PURCHASE AGREEMENT (the “Agreement”) is made as of May 1, 2006 (the
“Effective Date”) by and among AngioDynamics, Inc., a Delaware corporation with a principal place of business located at 603 Queensbury Avenue, Queensbury, New York 12804 (“AngioDynamics”), Medron, Inc., a Utah corporation with a
principal place of business located at 1518 South Gladiola Street, Salt Lake City, Utah 84104 (“Medron”), Ronald Wortley, an individual residing at 3129 Old Ridge Circle, Salt Lake City, Utah 84121 (“Wortley”) and Eric King, an
individual residing at 3001 Chimney Rock Circle, West Jordan, Utah 84064 (“King”). 
 RECITALS 
 WHEREAS, Medron is the owner of certain proprietary technology relating to a “*** Vascular Access Port” (the “Patent Pending
Technology”) for which a provisional patent application has been filed with the United States Patent and Trademark Office, identified as Serial Number *** US, filed September 30, 2005 (the “Provisional Application”) (any non-provisional patent application claiming priority to the Provisional Application shall be referred to as a
“Pending Application”); 
 WHEREAS, AngioDynamics desires to acquire the Patent Pending Technology and diligently pursue
prosecution of patent rights directed to the Patent Pending Technology for purposes of manufacturing, marketing and selling proprietary, legally and commercially saleable *** Vascular Access Ports with ***, following administrative approval (the
“Product”); and 
 WHEREAS, AngioDynamics desires to purchase and Medron, Wortley, and King desire to sell to AngioDynamics each of
their entire and collective rights, titles and interests in and to the Patent Pending Technology, the Provisional Application and any subsequent Pending Applications pursuant to the terms and conditions stated in this Agreement. 
 TERMS 
 NOW THEREFORE, in
consideration of the matters recited and of the mutual representations, warranties, covenants and agreements set forth in this Agreement, the parties agree as follows: 
 1. Sale and Assignment of Patent and Potential Trademark Rights. 
 (a) Subject to the terms and
conditions of this Agreement, Medron, Wortley and King agree to collectively sell, transfer, convey and assign to AngioDynamics each of their entire and collective rights, titles and interests in and to the Patent Pending Technology, the

	***	Confidential material redacted and filed separately with the Commission. 

  

					
	Final Agreement-Angio-Medron	  		  	May 1, 2006

 Provisional Application and any subsequent Pending Applications that are related to the Patent Pending Technology. In
furtherance thereof, concurrent with their execution of this Agreement, Medron, Wortley and King shall execute an assignment to AngioDynamics of their collective and entire patent rights with respect to the Patent Pending Technology and the
Provisional Application substantially in the form of an assignment as set forth in Exhibit A. In addition, Wortley and King shall execute all necessary papers, including a Declaration of Inventorship regarding the Patent Pending
Technology, an assignment substantially in the form of the assignment set forth in Exhibit A1 conveying their entire right, title, and interest in and to the Pending Application to AngioDynamics, and a Power of Attorney providing
AngioDynamics’ counsel with full authority to prosecute the Pending Application before the United States Patent and Trademark Office, and shall otherwise fully cooperate with and execute any and all additional documents necessary for
AngioDynamics to fully prosecute the Pending Application. 
 (b) AngioDynamics will use reasonable commercial efforts to file a Pending
Application with the U.S. Patent and Trademark Office and, at its sole discretion, counter-part foreign, non-provisional patent application(s) claiming priority to the Provisional Application. Medron shall cause all proper inventors of the invention
claimed in any Pending Application to cooperate with AngioDynamics and AngioDynamics’ patent counsel for purposes of preparing, reviewing, commenting upon, and executing any and all documents necessary or convenient for properly filing and
prosecuting such Pending Application with the proper authorities and to fully vest title in the Pending Application with AngioDynamics. 
 (c) In the event Medron, Wortley, or King develops enhancements to the Patent Pending Technology (“Improvements”) following the Effective Date, Medron, Wortley, and King shall promptly disclose such Improvements to AngioDynamics
and cause the inventors of such Improvements to cooperate with AngioDynamics and AngioDynamics’ patent counsel for the purposes of preparing, reviewing, commenting upon, and executing all necessary or convenient documents for filing with the
proper authorities to file and prosecute patent applications claiming such Improvements and convey all right, title and interest in and to the Improvements to AngioDynamics, including all patent rights associated therewith. AngioDynamics shall use
reasonable commercial efforts to file a U.S. and, at its sole discretion, counter-part foreign, non-provisional patent application(s) claiming the Improvements. 
 (d) Following the Effective Date of this Agreement, Medron shall provide assistance and shall cause its employees and agents to assist AngioDynamics with AngioDynamics’ Product development efforts to
commercialize the Patent Pending Technology, and to file and/or prosecute the Provisional Application and any subsequent Pending Application and/or Improvements in order to develop the Product. 
 (e) Medron hereby assigns to AngioDynamics its entire right, title and interest in and to the “Potential Trademarks” set forth in Exhibit
A2 together with all goodwill symbolized thereby. 
 2. No Assumption of Liabilities. AngioDynamics shall not assume, or in
any way be responsible for, any liability or obligation of any kind or nature whatsoever of Medron, Wortley or King as a result of the execution and delivery of this Agreement or the consummation of any transaction contemplated by this Agreement.

  

					
	Final Agreement-Angio-Medron	  	2	  	May 1, 2006

 3. Payment. Following the Effective Date of this Agreement, and in consideration of Medron’s,
Wortley’s and King’s assignment of patent rights of the Patent Pending Technology, the Provisional Application and any subsequent Pending Applications according to Section 1 of this Agreement, Medron’s, Wortley’s and
King’s obligations under this Agreement and related documents, AngioDynamics shall pay Medron, pursuant to the following schedule, provided that AngioDynamics shall not be liable to Medron for any payment until the event corresponding to each
such payment has been satisfactorily completed pursuant to the terms of this Agreement: 
 (a) $500,000 to Medron upon the Effective Date of
this Agreement and Medron’s, Wortley’s and King’s assignments of patent rights of the Patent Pending Technology, the Provisional Application and any subsequent Pending Applications to AngioDynamics; 
 (b) $1,500,000 upon the execution of an agreement between AngioDynamics and *** for the *** U.S. Patent Application, Serial Number *** (the “*** Application”); 
 If AngioDynamics fails to make this $1,500,000 million payment by September 1, 2006, then all Patent Pending Technology, along with all prototypes, all regulatory filings, all intellectual property applications
and work product and all inventory that AngioDynamics has received from Medron shall immediately be assigned and transferred to Medron and AngioDynamics shall retain no rights. AngioDynamics will, at no cost to Medron, immediately execute all
necessary or convenient documents to effect this assignment and transfer; 
 (c) $3,500,000 to Medron on the twenty-four (24) month
anniversary of the Effective Date of this Agreement, or upon the first commercial sale of the Product by AngioDynamics, whichever is earlier; 
 (d) $2,500,000 to Medron upon issuance within ten (10) years of the Effective Date of this Agreement of a patent by the US Patent and Trademark Office claiming priority to the Provisional Application or any issuance of a patent to
AngioDynamics within ten (10) years of the Effective Date of this Agreement in which Wortley and King are inventors and that claims Patent Pending Technology, but that may not have claimed the priority date of the Provisional Application, with
a minimum claim scope of a vascular access port, comprising a housing and ***. 
 4. Future Cooperation. Following the Effective Date,
Medron, Wortley and King shall cooperate with AngioDynamics to reasonably perform necessary or convenient acts in connection with the full prosecution of the Pending Applications and development of the Patent Pending Technology; including execution
of all documents and assignments associated with the prosecution and providing technical assistance as needed in the review of and in response to “Office Actions”. However, AngioDynamics shall not incur any additional costs or expenses or
pay any additional sums to Medron, Wortley and/or King, other than incidental out-of-pocket expenses (but not salaries, fees or commissions or any similar sums) incurred at the request of AngioDynamics. 
  

	***	Confidential material redacted and filed separately with the Commission. 

  

					
	Final Agreement-Angio-Medron	  	3	  	May 1, 2006

 5. Modification of Design. Following the Effective Date, Medron, Wortley and King shall be
responsible for design modifications to produce a *** Vascular Access Port, ***, by June 1, 2006. At no
additional cost or expense to AngioDynamics, Medron, Wortley and King will promptly transfer, convey and assign to AngioDynamics and AngioDynamics agrees to accept and acquire all documentation, materials and tooling related to the Patent Pending
Technology, including specifications of design, materials, adhesives and tooling. Medron, Wortley and King will cooperate with AngioDynamics concerning completion of design development and regulatory approval. 
 6. Breach. 
 (a) If any of the parties
is in material breach of this Agreement or any obligation hereunder, the party contending there is a breach (the “Charging Party”) may give written notice to the “Accused Party” of the nature of the breach and shall provide sixty
(60) days after the giving of such notice for the breach to be cured to the reasonable satisfaction of the Charging Party. If such breach is not cured to the reasonable satisfaction of the Charging Party, the Charging Party by notice to the
Accused Party shall have the right to terminate this Agreement and to seek damages from the Accused Party for breach of this Agreement. 
 (b) The parties shall agree to submit disputes arising under this Agreement to a neutral arbitration panel, familiar with patent law, with the costs being shared equally by the parties and the arbitration being binding and conducted in
accordance with the Rules of the American Arbitration Association. The arbitration panel shall be jointly selected by AngioDynamics and Medron. If AngioDynamics and Medron are unable to agree on an arbitration panel within fifteen (15) business
days after the written request of either one, each shall select an arbitration panel and the two arbitration panels shall mutually select a neutral arbitration panel, familiar with patent law, whose decision shall be binding on all parties. Any
arbitration brought pursuant to this provision shall be conducted in Albany, New York, if brought by AngioDynamics or Salt Lake City, Utah if brought by Medron. 
 7. Representations and Warranties of Medron, Wortley and King. Medron, Wortley and King make the following representations and warranties to AngioDynamics, each of which shall survive the closing of this
Agreement: 
 (a) Exclusivity. Wortley and King are the only inventors listed on the Provisional Application, no other inventors exist
and one hundred percent (100%) of the rights to the Provisional Application are currently assigned to Medron. 
 (b)
Authority/Binding Obligations. Medron, Wortley and King have all requisite legal capacity, power and authority, including the approval of Medron’s board of directors, to execute, perform, carry out and consummate the transactions
contemplated in this 
  

	***	Confidential material redacted and filed separately with the Commission. 

  

					
	Final Agreement-Angio-Medron	  	4	  	May 1, 2006

 Agreement. This Agreement and all documents and instruments to be executed and delivered hereunder have been duly
authorized by all necessary corporate action on the part of Medron, Wortley and King and constitute valid and binding obligations of Medron, Wortley and King enforceable against each in accordance with their terms. 
 (c) Patent Rights. Schedule 7(c) contains an accurate and complete list of all applicable registration and identification numbers
with respect to the Patent Pending Technology as set forth in the Provisional Application. Medron, Wortley and King collectively own all right, title and interest in and to all of the Patent Pending Technology and the Provisional Application, pay no
royalties to anyone with respect to this technology except as disclosed on Schedule 7(c), and have the full and lawful right to bring any actions for the infringement thereof. Neither Medron, Wortley or King have granted any licenses
or other rights to use the Patent Pending Technology and/or the Provisional Application except as described on Schedule 7(c). To the knowledge of Medron, Wortley, or King, no process, method or material employed in the Patent Pending
Technology and/or the Provisional Application infringes any patent or trademark, service mark, trade name, copyright or is in conflict with any proprietary right of another except as disclosed on Schedule 7(c). Except as disclosed on
Schedule 7(c), to the knowledge of Medron, Wortley, or King, no third-party is infringing or potentially infringing on the Patent Pending Technology and/or the Provisional Application. 
 (d) Organizational Authority. Medron is a corporation duly organized and validly existing and in good standing under the laws of the State of Utah
and it has all requisite power and authority to carry on its business as presently engaged. Medron has delivered to AngioDynamics or its counsel complete and correct copies of the certificate or articles of incorporation and bylaws of Medron, in
each case as amended to the Effective Date of this Agreement. 
 (e) Governmental Consents. Except as disclosed in Schedule
7(e), no consent, approval, order or authorization of, or registration, declaration or filing with, any court, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign, is required to be
obtained by Medron, Wortley or King in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated thereby. 
 (f) Capital Structure. As of the Effective Date, the shareholders of Medron are as disclosed on Schedule 7(f) and there are no outstanding warrants, options or rights entitling any individual or
entity the right to acquire any additional shares of Medron. 
 (g) No Default or Litigation. To the knowledge of Medron, Wortley, or
King, Medron is not in violation of or in default under any law, rule, regulation or ordinance, or any order of any court or federal, state, provincial, municipal or other governmental department, commission, board, bureau, agency or instrumentality
which could have a material adverse impact on the assets or the business of Medron. To the knowledge of Medron, Wortley or King, there are no private or public lawsuits, proceedings, claims, unsatisfied judgments, penalties or awards or governmental
investigations or eminent domain or condemnation proceedings pending or threatened against Medron or its assets or its business, and there is no basis for any as yet unasserted claims or actions except as described on Schedule 7(g).

  

					
	Final Agreement-Angio-Medron	  	5	  	May 1, 2006

 (h) No Conflict. Neither the execution, delivery and performance of this Agreement nor the
consummation of the transactions contemplated thereby, nor compliance with the provisions thereof will conflict with, or result in any violations of, or cause a default under, or give rise to a right of termination, amendment, cancellation or
acceleration of any obligation contained in, or the loss of any material benefit under, or result in the creation of any lien upon any of the properties or assets of Medron under any term, condition or provision of (i) the certificate or
articles of incorporation or bylaws of Medron; (ii) any loan or credit agreement, note, bond, mortgage, indenture, lease or other material agreement; or (iii) any judgment, order, decree, statute, law, ordinance, rule or regulation
applicable to Medron, Wortley or King or their respective properties or assets. 
 (i) No Third-Party Agreements. Neither the
execution, delivery or performance of this Agreement, nor the actions contemplated to be taken by Medron, Wortley or King hereunder, are prohibited by or will be in violation of any obligations or agreements Medron, Wortley and/or King have to or
with any third-party. 
 (j) Broker Fees. Neither Medron, Wortley nor King has engaged or authorized a broker, investment banker or
other person to act on its behalf, directly or indirectly, as a broker or finder who might be entitled to a fee, commission or other remuneration in connection with the transactions contemplated by this Agreement. 
 (k) Design History File. Medron, Wortley and King will cooperate with AngioDynamics concerning completion of design, development, Design History
File, process validation of processes performed by Medron, and regulatory approvals (including US FDA 510(k) submission and international regulatory approvals). 
 (l) No Public Disclosure. Medron, Wortley and King have not made any public disclosure that in any way has compromised either the U.S. or foreign patent rights with respect to the Patent Pending Technology.

 8. Representations and Warranties of AngioDynamics: AngioDynamics hereby makes the following representations and warranties to
Medron, Wortley and King, each of which shall survive the closing of this Agreement: 
 (a) Authority/Binding Obligations.
AngioDynamics has all requisite power and authority, including the approval of its board of directors, to execute, perform, carry out and consummate the transactions contemplated in this Agreement. This Agreement and all documents and instruments to
be executed and delivered hereunder have been duly authorized by all necessary corporate action on the part of AngioDynamics and constitute legal, valid and binding obligations of AngioDynamics enforceable in accordance with their terms. 

(b) Organizational Authority. AngioDynamics is a corporation duly organized and validly existing and in good standing under the laws of the
State of Delaware and has all requisite power and authority to carry on its business as presently engaged. 
  

					
	Final Agreement-Angio-Medron	  	6	  	May 1, 2006

 (c) Design History File. AngioDynamics shall be responsible for the Design History File and 510(k)
submission and international regulatory submissions with respect to the subject matter of this Agreement. 
 9. Indemnification.

 (a) Indemnification by AngioDynamics. AngioDynamics agrees to indemnify and hold Medron, its officers, directors, employees,
successors and assigns, Wortley and King harmless from and against any and all Loss that they, or any of them, may incur to the extent that such Loss arises out of or results from (i) a breach of any representation made or warranty given in
this Agreement by AngioDynamics; (ii) a breach of any term or condition of this Agreement by AngioDynamics; and (iii) any illness, injury or death arising from the use of the Product. 
 (b) Indemnification by Medron, Wortley and King. Medron, Wortley and King each agrees to indemnify and hold AngioDynamics its officers, directors,
employees, successors and assigns harmless from and against any and all Loss that that they, or any of them, may incur to the extent that such Loss arises out of or results from (i) a breach of any representation made or warranty given in this
Agreement by Medron, Wortley or King; and (ii) a breach of any term or condition of this Agreement by Medron, Wortley or King. 
 (c)
Indemnification Procedure. The party seeking indemnification (the “Indemnified Party”) shall (i) give the other party (the “Indemnifying Party”) notice of the relevant claim; however, the failure to notify the
Indemnifying Party or Parties shall not relieve any Indemnifying Party of any liability that it may have to the Indemnified Party except to the extent that such failure to notify shall have resulted in a waiver of any lawful and valid affirmative
defense to any such claim or otherwise materially prejudices the Indemnifying Party or Parties in connection with the administration or defense of any such claim; (ii) cooperate with the Indemnifying Party, at the Indemnifying Party’s
expense, in the defense of such claim; and (iii) at the sole discretion of the Indemnified Party (x) control the defense and settlement of any such claim at the Indemnifying Party’s expense or (y) give the Indemnifying Party the
right to control the defense and settlement of any such claim at the Indemnifying Party’s expense, provided, however, that the Indemnifying Party shall not enter into any settlement that affects the Indemnified Party’s rights or interests
without the Indemnified Party’s prior written approval, such approval not to be unreasonably withheld, conditioned or delayed. 
 (d)
For purposes of this Agreement, “Loss” shall mean any and all damages, fines, fees, penalties, deficiencies, liabilities, losses and expenses, including without limitation, interest, reasonable expenses of investigation, court costs,
reasonable fees and expenses of attorneys, accountants and other experts or other expenses of litigation or other proceedings or of any claim, default or assessment (such fees and expenses to include all fees and expenses, including without
limitation fees and expenses of attorneys, incurred in connection with (i) the investigation or defense of any third party claims or (ii) successfully asserting or disputing any rights under this Agreement against any party hereto or
otherwise). 
 10. Surviving Obligations. Termination or expiration of this Agreement shall not relieve any of the parties of their
respective obligations under Sections 6, 7, 8, 9, 10, 11 or 17. 
  

					
	Final Agreement-Angio-Medron	  	7	  	May 1, 2006

 11. Governing Law/Venue. This Agreement shall be governed by the laws of the State of New York,
regardless of conflict of law rules. 
 12. No Assignment. Neither this Agreement, nor any rights or obligations under it, may be
assigned by any party without the prior written consent of the other parties. 
 13. Successors and Assigns. This Agreement shall
benefit and be binding upon the parties and their successors, heirs, executors, personal representatives, and assigns. 
 14. Entire
Agreement. This Agreement and the exhibits hereto and the documents referred to herein and therein constitute the entire understanding and agreements of the parties hereto with respect to the subject matter hereof and supersede all prior and
contemporaneous agreements or understandings, inducements or conditions, expressed or implied, written or oral, between the parties with respect hereto. The express terms hereof control and supersede any course of performance or usage of the trade
inconsistent with any of the terms hereof. 
 15. Notices. All notices and other communications pursuant to this Agreement shall be in
writing and deemed to be sufficient if contained in a written instrument and shall be deemed given if delivered personally, telecopied, sent by nationally-recognized overnight courier or mailed by registered or certified mail (return receipt
requested), postage prepaid, to the parties at the following address (or at such other address for a party as shall be specified by like notice): 
 If to AngioDynamics: 
 AngioDynamics, Inc. 
 603 Queensbury Avenue 
 Queensbury, New York 12804 
 Attention: Eamonn Hobbs 
 Telecopier:
(518) 798-3625 
 With copy to: 
 Gregory J. Champion, Esq. 
 Bond, Schoeneck & King, PLLC 
 111 Washington Avenue 
 Albany, New York
12210-2211 
 Telecopier: (518) 533-3299 
 If to Medron, Inc.: 
 Medron, Inc. 
 1518 South Gladiola Street 
 Salt Lake City,
Utah 84104 
 Attention: Ronald Wortley 
 Telecopier: (801) 974-3063 
  

					
	Final Agreement-Angio-Medron	  	8	  	May 1, 2006

 If to Ronald Wortley: 
 3129 Old Ridge Circle 
 Salt Lake City, Utah
84121 
 Telecopier: (801) 974-3063 
 If to Eric King: 
 3001 Chimney Rock Circle 
 West Jordan, Utah 84064 
 Telecopier: (801) 974-3063 
 With copy in each case to: 
 Kirton & McConkie 
 ATTN: Kenneth E. Horton 
 1800 Eagle Gate Tower 
 60 East South Temple 
 P.O. Box 45120 
 Salt Lake City, UT 84145-0120

 16. Waiver. Any term or provision of this Agreement may be waived (either generally or in a particular instance and either
retroactively or prospectively) only by a writing signed by the party or parties to be bound thereby. The waiver of any provision of this Agreement, or of any breach of this Agreement, shall not constitute a subsequent waiver of any provision or
breach. 
 17. Confidentiality: Press Releases. None of the parties (nor any of their employees, officers or representatives) shall
(i) make any press release or announcement concerning the transactions contemplated hereby or the terms hereof, or (ii) reveal or discuss the terms of this Agreement or the transactions contemplated hereby with any person (other than their
respective professionals in the course of performing their professional services), without prior written consent of the other parties, except as such party in good faith (based upon advise of counsel) believes is required by law and following notice
to the other party. 
 18. Further Assurances. At any time from and after the Effective Date, each of the parties shall, without
additional consideration, upon the request of another party, execute, acknowledge, and deliver such documents, and will take such other action consistent with the terms of this Agreement, as may be reasonably required to consummate the transactions
contemplated by this Agreement and to permit each of the parties to enjoy their prospective rights and benefits hereunder. 
 19.
Expenses. Medron, Wortley and King, on one hand, and AngioDynamics on the other, will bear their own respective expenses and legal fees incurred with respect to this Agreement and the transactions contemplated hereby. 
  

					
	Final Agreement-Angio-Medron	  	9	  	May 1, 2006

 20. Amendment. This Agreement may be modified or amended only upon the written consent of all
parties to this Agreement. 
 21. Counterparts. This Agreement may be executed in one or more counterparts, which together shall form
but one original document. Delivery of an executed signature page to this Agreement by facsimile transmission shall be as effective as delivery of a manually signed counterpart. 
 * * * 
  

					
	Final Agreement-Angio-Medron	  	10	  	May 1, 2006

 IN WITNESS WHEREOF, the parties have executed this Asset Purchase Agreement as of the date indicated by
their signature. 
  

			
	ANGIODYNAMICS, INC.
		
	By:	 	  

		 	William M. Appling
	Title:	 	Vice President, Research
	Date:	 	  

	
	MEDRON, INC.
		
	By:	 	  

		 	Ronald Wortley
	Title:	 	President
	Date:	 	  

	
	RONALD WORTLEY
	
	  

	Date:	 	  

	
	ERIC KING
	
	  

	Date:	 	  

  

					
	Final Agreement-Angio-Medron	  	11	  	May 1, 2006

 Exhibit A 
 Medron, Wortley and King Assignment 

 ASSIGNMENT 
 WHEREAS, We, Ronald Wortley, an individual and citizen of the United States residing at 3129 Old Ridge Circle, Salt Lake City, Utah 84121, Eric King, an individual and citizen of the United States residing at
3001 Chimney Rock Circle, West Jordan, Utah 84064, (collectively “INVENTORS”), have made certain new and useful improvements in a *** Vascular Port, for which a provisional application for Letters Patent of the United States has been filed and assigned serial number *** and a filing date of September 30, 2005 (“Provisional
Application”), and for which non-provisional Letters Patent will be sought. 
 WHEREAS, INVENTORS have conveyed their entire
right, title and interest in and to the Provisional Application to Medron, Inc., a Utah Corporation with a principal place of business at 1518 South Gladiola Street, Salt Lake City, Utah 84104 (“ASSIGNOR”). 
 WHEREAS, AngioDynamics, Inc., a corporation incorporated under the laws of the State of Delaware, and having an address at 603 Queensbury Avenue,
Queensbury, New York 12804 (“ASSIGNEE”) is desirous of acquiring the entire right and interest in the Provisional Application; 
 NOW, THEREFORE, BE IT KNOWN that for and in consideration of the sum of one dollar ($1.00) and other good and valuable consideration to us in hand paid, the receipt of which is hereby duly and fully acknowledged, INVENTORS, Ronald
Wortley and Eric King hereby represent and warrant that we have conveyed our entire right, title and interest in and to the Provisional Application to ASSIGNOR, Medron, Inc., and ASSIGNOR, Medron, Inc. has sold and BY THESE PRESENTS does sell,
assign, transfer and set over unto the said ASSIGNEE, AngioDynamics, Inc., any and all of its entire right, title and interest in and to the aforesaid Provisional Application, and all non-provisional patent applications containing a claim of
priority thereto, including all divisions, continuations, continuations-in-part, and foreign rights thereunder. 
  

					
	Date:                     	 		 	  

		 		 	Ronald Wortley
	STATE OF UTAH	 	)	 	
		 	) ss.:                        	 	
	COUNTY OF                                    
 	 	)	 	

 On the          day of
             in the year              before me, the undersigned, a notary public in and for said State, personally
appeared                     
                                        
personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies),
and that by his/her/their signature(s) on the instrument, the individual(s) or the person upon behalf of which the individual(s) acted, executed this instrument. 

			
		  	  

		
	  
	  	

  

	***	Confidential material redacted and filed separately with the Commission. 

											
		  		  		  		  	 Notary Public

					
	 Date:                     
	  		  		  		  	  

		  		  		  		  	 Eric King

						
	 STATE OF UTAH
	  	)	  		  		  		  	
		  	)	  	ss.:	  		  		  	
	 COUNTY OF                                    
     
	  	)	  		  		  		  	

 On the      day of
                     in the year          before me, the undersigned, a notary public in and
for said State, personally appeared                     
                             personally known to me or proved to me on the basis of satisfactory
evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their signature(s) on the instrument, the
individual(s) or the person upon behalf of which the individual(s) acted, executed this instrument. 
  

							
		  	  
	  		  	
	 Notary Public
	  		  		  	

  

											
	 Date:                     
	  		  		  		  	  

		  		  		  		  	 Medron, Inc.

						
		  		  		  		  	By:	  	  

		  		  		  		  	Its:	  	  

		  		  		  		  		  	
	 STATE OF UTAH
	  	)	  		  		  		  	
		  	)	  	ss.:	  		  		  	
	 COUNTY OF                                    
     
	  	)	  		  		  		  	

 On the      day of
                     in the year          before me, the undersigned, a notary public in and
for said State, personally appeared                     
                             personally known to me or proved to me on the basis of satisfactory
evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their signature(s) on the instrument, the
individual(s) or the person upon behalf of which the individual(s) acted, executed this instrument. 
  

							
		  	  
	  		  	
	 Notary Public
	  		  		  	

 Exhibit A1 
 Wortley and King Assignment 

 ASSIGNMENT 
 WHEREAS, We, Ronald Wortley, an individual and citizen of the United States residing at 3129 Old Ridge Circle, Salt Lake City, Utah 84121, and Eric King, an individual and citizen of the United States residing
at 3001 Chimney Rock Circle, West Jordan, Utah 84064, (collectively “ASSIGNORS”), have made certain new and useful improvements in an *** Vascular Port, for which United States Letters Patent is being sought (“Patent Application”). 
 WHEREAS, AngioDynamics, Inc., a corporation incorporated under the laws of the State of Delaware, and having an address at 603 Queensbury Avenue, Queensbury, New York 12804 (“ASSIGNEE”) is desirous of
acquiring the entire right and interest in the Patent Application; 
 NOW, THEREFORE, BE IT KNOWN that for and in consideration of the
sum of one dollar ($1.00) and other good and valuable consideration to us in hand paid, the receipt of which is hereby duly and fully acknowledged, Ronald Wortley and Eric King (ASSIGNORS) have sold and BY THESE PRESENTS do sell, assign, transfer
and set over unto the said AngioDynamics, Inc. (ASSIGNEE) any and all of their entire right, title and interest in and to the aforesaid Patent Application, and all divisions, continuations, continuations-in-part, and foreign rights thereunder.

  

					
	Date:                     	 		 	  

		 		 	Ronald Wortley
	STATE OF UTAH	 	)	 	
		 	) ss.:                        	 	
	COUNTY OF                                    
 	 	)	 	

 On the          day of
             in the year              before me, the undersigned, a notary public in and for said State, personally
appeared                     
                                     personally known to me or
proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their capacity(ies), and that by his/her/their
signature(s) on the instrument, the individual(s) or the person upon behalf of which the individual(s) acted, executed this instrument. 
  

	
	  

	 Notary Public

  

	***	Confidential material redacted and filed separately with the Commission. 

					
	Date:                     	 		 	  

		 		 	Eric King
	STATE OF UTAH	 	)	 	
		 	) ss.:                        	 	
	COUNTY OF                                    
 	 	)	 	

 On the          day of
             in the year              before me, the undersigned, a notary public in and for said State, personally
appeared                     
                                        
     personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is (are) subscribed to the within instrument and acknowledged to me that he/she/they executed the same in
his/her/their capacity(ies), and that by his/her/their signature(s) on the instrument, the individual(s) or the person upon behalf of which the individual(s) acted, executed this instrument. 
  

			
		 	  

	 Notary Public
	 	

 Exhibit A2 
 Potential Trademarks 
  

			
	Mark	  	Goods
	SURE SIGHT	  	Vascular Ports

 Schedule 7 (c) 
 Patent Rights 
  

	•	 	Registration and identification numbers with respect to the Patent Pending Technology and the Provisional Application. 

 US Provisional Pending Patent Application, Serial Number *** filed September 30, 2005 
  

	•	 	Royalties paid by Medron, Wortley and King to a third-party with respect to the Patent Pending Technology and/or the Provisional Application. 

 None 
  

	•	 	Third-party licenses or other rights granted with respect to use of the Patent Pending Technology and/or the Provisional Application. 

 None 
  

	•	 	Processes methods or materials employed in the Patent Pending Technology and/or the Provisional Application that infringes any patent or trademark, service mark, trade name,
copyright or is in conflict with any proprietary right of another. 

 None 
  

	•	 	Third-parties infringing or potentially infringing on the Patent Pending Technology and/or the Provisional Application. 

 None 
  

	***	Confidential material redacted and filed separately with the Commission. 

 Schedule 7 (e) 
 Government Consents 
 None 

 Schedule 7 (f) 
 Capital Structure 
  

			
	Shareholder Name	  	Number of Shares Held
	Ron Wortley	  	 10,000 (100%)

 Schedule 7 (g) 
 Defaults or Litigation 
 None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]